<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394224</url>
  </required_header>
  <id_info>
    <org_study_id>N01377</org_study_id>
    <secondary_id>2011-000827-34</secondary_id>
    <nct_id>NCT01394224</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects</brief_title>
  <official_title>A Single Site, Open-label, Randomized, Single-dose, Two-way Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence, Safety &amp; Tolerability of Levetiracetam Administered as an Oral Tablet or Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics(PK) and evaluate the
      bioequivalence of levetiracetam (LEV) following a single 15-minutes IV infusion of 1500 mg
      and a single oral dose(tablets) of 1500 mg in healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration versus time curve from hour 0 to the time with a last quantifiable level (AUCo-t)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours (could be less than 36 hours if the last quantifiable concentration is below limit of quantification), following single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at the end of infusion (C15' )</measure>
    <time_frame>At 15 minutes after termination of the15-minutes infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to infinity (AUC)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean resident time (MRT)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life(t1/2)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First order terminal elimination rate constant (Î»z )</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance after oral administration (CL/F) or after IV infusion (CL)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution after oral administration(Vz/F) or after IV infusion(Vz)</measure>
    <time_frame>Multiple sampling from 0 to 36 hours following single dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Levetiracetam IV Infusion (1500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Levetiracetam tablets (1500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose</description>
    <arm_group_label>Levetiracetam IV Infusion (1500 mg)</arm_group_label>
    <other_name>E-Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose</description>
    <arm_group_label>Levetiracetam tablets (1500 mg)</arm_group_label>
    <other_name>E-Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male and female volunteers with the age between 20 and 55 years old

        Exclusion Criteria:

          -  Subject has participated or is participating in any other clinical studies of
             investigational drug or another IMP within the last 3 months

          -  Subject is not healthy (eg, taking any drug treatments, excessive amount of alcohol,
             cigarettes or caffeine, having any medical or emotional/psychological problems, a
             drug/alcohol abuse, having abnormal safety parameters)

          -  Subject is pregnant or lactating female.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Japanese</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

